Publications by authors named "Sushma Kumar"

Claim this Profile
N
Nanopriming with zinc oxide nanoparticle boosts seed vigour, photosynthesis, osmolytes accumulation and antioxidant activity in tomato.
Sushma Mudlupura Kumar, Sangita Yadav, Ravish Choudhary, Anbalagan Anumantharaj, Ayushi Yadav, Praveen Kumar Singh, Shiv Kumar Yadav

Sci Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Host-gut microbiota derived secondary metabolite mediated regulation of Wnt/β-catenin pathway: a potential therapeutic axis in IBD and CRC.
Sushma S Kumar, Ashna Fathima, Preeti Srihari, Trinath Jamma

Front Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Chloe Orkin, Jean-Michel Molina, Pedro Cahn, Johannes Lombaard, Khuanchai Supparatpinyo, Sushma Kumar

Lancet HIV· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molnupiravir: Mechanism of action, clinical, and translational science.
Brian M Maas, Julie Strizki, Randy R Miller, Sushma Kumar, Michelle Brown

Clin Transl Sci· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial.
Chloe Orkin, Kathleen E Squires, Jean-Michel Molina, Paul E Sax, Otto Sussmann, Sushma Kumar

Clin Infect Dis· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine.
Mark Nelson, Alan Winston, Andrew Hill, Rosie Mngqibisa, Ayesha Bassa, Sushma Kumar

AIDS· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development.
Elizabeth Anne Martin, Ming-Tain Lai, Winnie Ngo, Meizhen Feng, Donald Graham, Sushma Kumar

J Acquir Immune Defic Syndr· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial.
Jose M Gatell, Javier O Morales-Ramirez, Debbie P Hagins, Melanie Thompson, Keikawus Arastéh, Sushma Kumar

Antivir Ther· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis.
Melanie Thompson, Chloe Orkin, Jean-Michel Molina, Paul Sax, Pedro Cahn, Sushma Kumar

Clin Infect Dis· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis.
Chloe Orkin, Jean-Michel Molina, Johan Lombaard, Edwin DeJesus, Anthony Rodgers, Sushma Kumar

Clin Infect Dis· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
Jean-Michel Molina, Kathleen Squires, Paul E Sax, Pedro Cahn, Johan Lombaard, Sushma Kumar

Lancet HIV· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations.
Alexander Wong, Deborah Goldstein, Josep Mallolas, Edwin DeJesus, Margaret Johnson, Sushma Kumar

J Acquir Immune Defic Syndr· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.
Margaret Johnson, Princy Kumar, Jean-Michel Molina, Giuliano Rizzardini, Pedro Cahn, Sushma Kumar

J Acquir Immune Defic Syndr· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.
Chloe Orkin, Kathleen E Squires, Jean-Michel Molina, Paul E Sax, Wing-Wai Wong, Sushma Kumar

Clin Infect Dis· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
Jean-Michel Molina, Kathleen Squires, Paul E Sax, Pedro Cahn, Johan Lombaard, Sushma Kumar

Lancet HIV· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.
Paul McNicholas, Regis A Vilchez, Wayne Greaves, Sushma Kumar, Chinyere Onyebuchi

J Clin Virol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women.
Vivian Brache, Regine Sitruk-Ware, Alistair Williams, Diana Blithe, Horacio Croxatto, Narender Kumar, Sushma Kumar

Contraception· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An initial pharmacokinetic study with a Metered Dose Transdermal Systemfor delivery of the progestogen Nestorone as a possible future contraceptive.
Ian S Fraser, Edith Weisberg, Narender Kumar, Sushma Kumar, Andrew J Humberstone

Contraception· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study.
Régine Sitruk-Ware, Geneviève Plu-Bureau, Joël Menard, Jacqueline Conard, Sushma Kumar

J Clin Endocrinol Metab· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard gel: a new formulation for "dual protection" contraception.
Regine Sitruk-Ware, Vivian Brache, Robin Maguire, Horacio Croxatto, Narender Kumar, Sushma Kumar

Contraception· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progesterone induces calcitonin expression in the baboon endometrium within the window of uterine receptivity.
Sushma Kumar, Allison Brudney, Yong-Pil Cheon, Asgerally T Fazleabas, Indrani C Bagchi

Biol Reprod· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis